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Abstract
Background: The expression level of osteopontin correlates with the metastatic potential of
several tumors. Osteopontin is a well-characterized ligand for the αvβ3 integrin. The present study
was undertaken to elucidate the possible role of osteopontin/αvβ3 signaling in prostate cancer cell
migration.
Results: We generated stable prostate cancer cell (PC3) lines that over-express osteopontin
(PC3/OPN), mutant OPN in the integrin binding-site (PC3/RGDΔRGA), and null for OPN (PC3/
SiRNA). The following observations were made in PC3/OPN cells as compared with PC3 cells: 1)
an increase in multinucleated giant cells and RANKL expression; 2) an increase in CD44 surface
expression, interaction of CD44/MMP-9 on the cell surface, MMP-9 activity in the conditioned
medium, and cell migration; 3) western blot analysis of concentrated conditioned medium exhibited
equal levels of MMP-9 protein in all PC3 cells. However, zymography analysis demonstrated that
the levels of MMP-9 activity in the conditioned media reflect the CD44 surface expression pattern
of the PC3 cell lines; 4) although MMP-9 and MMP-2 are secreted by PC3 cells, only the secretion
of MMP-9 is regulated by OPN expression. A strong down regulation of the above-mentioned
processes was observed in PC3/OPN (RGA) and PC3/SiRNA cells. PC3/OPN cells treated with
bisphosphonate (BP) reproduce the down-regulation observed in PC3/OPN (RGA) and PC3/
SiRNA cells.
Conclusion: Rho signaling plays a crucial role in CD44 surface expression. BPs inhibits the
mevalonate pathway, which in turn, prevents the prenylation of a number of small GTPases.
Attenuation of Rho GTPase activation by BPs may have contributed to the down regulation of cell
surface CD44/MMP-9 interaction, MMP-9 activation/secretion, and cell migration. Taken together,
these observations suggest that CD44 surface expression is an important event in the activation of
MMP-9 and migration of prostate cancer cells. The various steps involved in the above mentioned
signaling pathway and/or the molecules regulating the activation of MMP-9 are potential therapeutic
target.
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Background
Prostate cancer is a disease of extensive metastases, with
secondary lesions occurring in lymph nodes, bones and
sometimes in visceral organs, such as the liver, lungs, and
even the brain. The advanced stage of prostatic carcinoma
eventually metastasizes to the bones in 85–100% of cases.
Although metastasis to bone, especially the spine, pelvis,
and ribs, is predominantly observed in prostate cancer
patients, the mechanism(s) underlying the predilection of
prostate cancer to metastasize to bone remains unclear.
Chemotactic experiments using extracts from various
organs have demonstrated that bone extracts are more
potent in attracting prostate cancer cells than other
extracts [1]. Some studies have demonstrated an elevated
expression of osteopontin (OPN) in highly invasive met-
astatic breast and prostate cancer cells [2-4]. OPN func-
tions both as a cell attachment and chemoattractive factor
in tumors, like breast and prostate cancers [5,6].
OPN interaction with integrin αvβ3 transduces cell-matrix
signaling directed to increased motility, invasion, and
angiogenesis [7]. Integrin αvβ3 has a role in the metastasis
of prostate cancer cells to bone by arbitrating adhesion to
and migration on OPN and vitronectin, which are com-
mon extra cellular matrix (ECM) proteins in bone micro-
environment. Adhesion of breast and prostate cancer cells
to bone marrow endothelial cell line (hBMECs) is directly
related to the surface expression of the hyaluronan recep-
tor CD44 [8]. De novo expression of CD44 and its variant
isoforms has been associated with aggressive behavior in
various tumors [9]. Also, CD44 expression on prostate
cancer cells (PC3) derived from bone metastases has been
shown to have a role in their selective adhesion to bone
marrow endothelium. PC3 cells exhibited a rapid and
strong adhesion to human bone marrow endothelial cell
line (hBMECs), and depletion of CD44 expression with
use of RNAi attenuated this adhesion [8]. We have
reported previously that OPN expression in human
melanoma cells increases CD44 surface expression, MMP-
2 secretion, and cell migration [10].
Matrix metalloproteinases (MMPs) have been implicated
in bone resorption and tumor progression [11]. In many
tumor cells, MMPs and CD44 were strongly expressed
[12]. The expression of MMPs and variant CD44 (vCD44)
correlates strongly with cancer cell invasiveness and
metastasis [13,14]. MMPs have a role in tissue remodeling
during development, bone resorption, wound healing,
and angiogenesis [15-17]. MMP-2 and MMP-9 are associ-
ated with metastasis of prostate cancer cells to bone [18].
CD44 associates with a proteolytic form of the matrix
metalloproteinase-9 (MMP-9) on the surface of mouse
mammary carcinoma and human melanoma cells. CD44
was shown to anchor MMP-9 on the cell surface. Disrup-
tion of CD44/MMP-9 cluster formation, by over expres-
sion of soluble or truncated cell surface CD44 reduces
tumor invasiveness in vivo [19].
Several MMP inhibitors have been investigated in clinical
trials for their efficacy in blocking tumor invasion.
Bisphosphonates (BPs) reduce the rate of damage caused
to bone. They inhibit osteoclast activity and, therefore, are
used to treat patients with osteolytic metastases. BPs
reduce osteoclast bone resorption and pain in prostate
cancer patients [20]. Furthermore, oral alendronate ther-
apy protects bone against tumor cell attachment and pos-
sibly prevents bone metastases [11]. Bisphosphonate
pretreatment of breast and prostate carcinoma cells inhib-
ited tumor cell invasion. These compounds did not
induce apoptosis in tumor cells to inhibit tumor invasion,
but they inhibited the proteolytic activity of metallopro-
teinases through chelation of zinc ions [20].
The present study supports the hypothesis that OPN/αvβ3
signaling-mediated CD44/MMP-9 complex formation on
the cell surface, MMP-9 secretion, and activity may play
important roles in prostate cancer cell migration. A mech-
anism for the activation and secretion of active MMP-9
has yet to be elucidated. Observations in PC3/SiRNA and
PC3/OPN (RGA) cells emphasize the novel role of OPN
and αvβ3 signaling pathway in these processes. CD44/
MMP-9 complex formation on the cell surface may repre-
sent a unique motility-enhancing signal in prostate cancer
cells, thereby promoting their invasiveness.
Results
Analysis of osteopontin expression in different PC3 clones 
and the effects of osteopontin expression on MMPs 
activity in conditioned media
To determine the OPN/αvβ3-mediated signaling mecha-
nisms involved in prostate cancer cell migration, we gen-
erated different PC3 cell lines as described in the Methods
section. OPN expression levels were detected by immuno-
blotting with an antibody to OPN (Figure 1A; top panel.
Approximately 10–15 clones were analyzed for high
expression of OPN by Western blotting with an antibody
to OPN. Among the clones tested, we chose one that
exhibited high expression (>10 times) of full length OPN
(clone C1; lane 4) and mutant (RGDΔRGA) OPN (Clone
C1; lane 5). Untransfected and pCEP-4 vector transfected
PC3 cells (lanes 1 and 2) were used as controls. To reduce
endogenous OPN in PC3 cells, we generated four different
OPN SiRNA constructs in the pSilencer vector (lanes 6–9).
Scrambled RNA constructs (lane 10) and vector (pSilencer
4.1-CMV neo vector) -transfected cells (lane 3) were used
as controls. A significant decrease in OPN expression was
observed in PC3 cells transfected with a SiRNA construct.
This construct was targeted to human OPN cDNA
sequence 383–403 (lane 7). Immunoblot that is shown inMolecular Cancer 2007, 6:18 http://www.molecular-cancer.com/content/6/1/18
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panel A was stripped and blotted with an antibody to
GAPDH (Figure 1A, bottom panel) as a loading control.
Several clones (10–15) were isolated from the SiRNA con-
struct targeted to human OPN cDNA sequence 383–403.
OPN levels were significantly reduced in five SiRNA
clones (C1–C5) as compared with scrambled RNA con-
structs and vector (pSilencer 4.1-CMV neo vector)-trans-
fected cells. To determine the effects of OPN levels on
MMP-9 activity, conditioned media was collected from
four independent clones that express high level of full
length OPN (B, lanes 3–6), mutant OPN (B; lanes 7–10)
and five independent SiRNA clones (C; lanes 3–7). These
conditioned media were used for gelatin zymogram anal-
ysis (Figure 1B and 1C).
Zymogram analysis
OPN functions as a paracrine and autocrine mediator of
prostate cancer growth and progression [25]. Cancer cells
express high level of MMPs that were shown to assist in
tumor initiation, invasion, and tumor metastasis [26].
Therefore, we investigated whether the secreted MMP-9
activity is associated with the OPN expression level. Gela-
tin zymography exhibited gelatinolytic activity of both
MMP-2 and MMP-9 in the conditioned media (Figure
1B). While MMP-2 activity remains the same, changes in
MMP-9 activity was observed in PC3 cell lines. MMP-9
activity was greatly enhanced in OPN over expressing
clones which are represented as C1–C4 (B, lanes 3–6) as
compared with PC3 cells (lane 2). MMP-9 activity is sig-
nificantly reduced in PC3/OPN (RGA) (B, lanes 7–10)
although these individual clones express maximum levels
of mutated OPN as shown in Figure 1A (lane 5). PC3/
SiRNA clones also exhibited maximum decrease in MMP-
9 activity. This corresponds to the OPN expression levels
(C, lanes 3–7). Conditioned medium from untransfected
PC3 cells (Lane 2 in Figures 1B and 1C) was used as con-
trol.
We found an increase in an active form of MMP-9 in PC3
cells. The secretion of this form is greatest in PC3/OPN
cells. To further confirm that the secreted MMP-9 is in the
active form, we incubated the conditioned medium (10
μg protein) with and without APMA (1 mM at 37°C; 15
min.). In the gelatin zymogram analysis, neither pro- nor
an intermittent latent form of MMP-9 was observed after
incubation with APMA (data not shown). This confirms
that PC3 cells secrete active MMP-9. Although, further
experiments are required to fully understand the signifi-
cance of this observation, it underlies the importance of
studying MMP-9 activity in cell migration. Constitutive
secretion of active MMP-9 in PC3 cells suggest that the sig-
naling molecule(s) or αvβ3-mediated signal transduction
pathway that regulates the activation of MMP-9 may be a
potential therapeutic target(s). αvβ3-mediated signal
transduction pathway or OPN expression has no signifi-
cant effect on the already low basal level activity of MMP-
2. Asterisks in Figure (1B and 1C) represent the clones
used for the present study.
Analysis of CD44 surface expression and migration in PC3 
cell lines
We assessed the surface levels of CD44 in PC3 cell lines.
PC3 cell lines were surface labeled with NHS-Biotin and
equal amount of protein lysates were immunoprecipi-
tated with an antibody to variant CD44 (vCD44 v3–v10)
and actin. Actin antibody was used as an internal control
for immunoprecipitation. Immunoblotting was per-
formed with an antibody to streptavidin-HRP to visualize
the surface expression of CD44 (Figure 2A). Surface
expression of CD44 splice variants (vCD44) was markedly
increased in PC3/OPN cells (Figure 2A, lane 2) as com-
pared with PC3 cells (lane 1). Lanes 5 and 6 represent
shorter exposure blots of lanes 1 and 2, respectively. Both
PC3/OPN (RGA) and PC3/SiRNA cells exhibited a
decrease in the surface expression of vCD44 (lanes 3 and
4). The blot shown in the Figure 2B was stripped and
immunoblotted with an antibody to actin. Immunoblot-
ting with an antibody to actin did not demonstrate a sig-
nificant change in the levels (Figure 2B) despite changes
in the surface levels of CD44 (Figure 2A). This indicates
that equal amount of lysate proteins were used for immu-
noprecipitation. Our results demonstrate a significant
increase in the surface expression of CD44 in PC3/OPN
cells.
Since there was an increase in MMP-9 activity in the con-
ditioned media of PC3/OPN cells (Figure 1B), we deter-
mine the surface levels of MMP-9 in PC3 cell lines (Figure
2C). Equal amounts of surface labeled lysates were immu-
noprecipitated with an antibody to MMP-9 and blotted
with streptavidin-HRP. There are no changes in the surface
levels of MMP-9 in PC3 cell lines, and only a single band
of MMP-9 protein (85–90 kDa) was detected in all cells
(Figure 2C). No changes in the surface levels of MMP-9
also serve as a biotinylation control for surface labeling.
This indicates that the biotinylation reaction was equally
efficient in all PC3 cell lines. Consistent with our previous
observation [22], the observed increase in the surface level
of CD44 is due to OPN/αvβ3 signaling as PC3/OPN
(RGA) cells exhibited a decrease in CD44 surface expres-
sion.
Wound closure assay
Having established that OPN expression increases secre-
tion of MMP-9, we next examined the functional conse-
quences of this in an in vitro by migration assay. PC3 cell
lines were subjected to wound closure assay (Figures 2D
and 2E). The decrease in wound size corresponds to the
increase in migration of cells. Migration was performedMolecular Cancer 2007, 6:18 http://www.molecular-cancer.com/content/6/1/18
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Analysis of the effects of osteopontin (OPN) expression on MMP-9 activity Figure 1
Analysis of the effects of osteopontin (OPN) expression on MMP-9 activity. A. OPN expression levels were meas-
ured in different PC3 cell lines (indicated below each lane) by immunoblotting analysis. Untransfected PC3 cells (lane 1), PC3 
cells transfected with pCEP4 vector (lane 2), pSilencer 4.1-CMV neo vector (lane 3), and Scrambled RNA construct (lane 10) 
were used as controls. Basal level expression of OPN was observed in these cells. An increase in OPN expression was 
observed in PC3 cells transfected with full length (PC3/OPN; lane 4) and mutated (PC3/OPN (RGA); lane 5) OPN cDNA. Indi-
vidual clones (denoted as C1) that express maximum level of OPN is used for the studies shown here (lanes 4 and 5). PC3 cells 
transfected with four different SiRNA constructs exhibited expression of different levels of OPN (lanes 6–9). Immunoblotting 
with an antibody to GAPDH was used as a loading control (lower panel in A). B and C: Analysis of MMPs activity in the 
conditioned media of different PC3 cell lines by gelatin zymography: Several individual clones (10–15) were isolated from 
PC3 cells transfected with different OPN constructs (full length, mutated (RGDΔRGA), and SiRNA). Conditioned media col-
lected from clones that express maximum (Figure B, lanes 3–10; C1–C4 in PC3/OPN and PC3/OPN(RGA)) and reduced levels 
(Figure C, lanes 3–7, C1–C5) of OPN protein were used for zymogram analysis Untransfected PC3 cells were used as control 
(lane1 in B and C). The activity of a recombinant MMP-9 protein containing pro- and active band was used as an identification 
marker (lane 1 in B and C). Gelatinolytic activities of both MMP-2 and MMP-9 are indicated by arrows (B and C). The results 
represent one of three separate experiments performed.Molecular Cancer 2007, 6:18 http://www.molecular-cancer.com/content/6/1/18
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Analysis of CD44 surface expression and migration in different PC3 cell lines Figure 2
Analysis of CD44 surface expression and migration in different PC3 cell lines. A-C. Analyses shown in Figures A-C 
were performed in the following PC3 cell lines: PC3 (lane 1), PC3/OPN (lane 2), PC3/OPN (RGA) (lane 3), and PC3/SiRNA 
(lane 4). Cells were surface- labeled with NHS-Biotin and lysates were immunoprecipitated with an antibody to vCD44 (V3-10) 
(A) or MMP-9 (C). Also, as an internal control, a monoclonal antibody to actin was added to vCD44 immunoprecipitation. 
Actin immunoprecipitation was used as an internal control for normalization. Expression of variant forms of CD44 was 
observed in PC3 cell lines. Immunoprecipitation with a species-specific non-immune serum did not show any protein bands in 
the immunoblotting analysis (data not shown). Shorter exposure blot for PC3 (lane 5) and PC3/OPN (lane 6) is shown. The 
immunoblot shown in A was stripped and blotted with an actin antibody (B). Detection of surface expression of MMP-9 by 
immunoblotting with streptavidin-HRP is shown in C. No changes in the surface levels of MMP-9 indicate that biotinylation 
reaction was equally efficient in the indicated PC3 cell lines. The results represent one of three experiments performed. D and 
E: Wound healing assay. Phase-contrast micrographs of PC3, PC3/OPN, PC3/OPN (RGA) and PC3/SiRNA cells at 0 h and 48 
h are shown. Results represent one of three experiments performed. Statistical analysis is provided as a graph at 0 h and 48 h 
in panel E. A significant increase in the migration of PC3/OPN, PC3, and PC3/OPN (RGA) cells was observed as compared 
with PC3/SiRNA cells. *** p < 0.001 and ** p < 0.01 vs. PC3/SiRNA cells. For each cell line, two plates were used per experi-
ment. Multiple uniform streaks (~7–9 streaks) were made on the monolayer culture for each cell line. The data are mean ± 
SEM of three experiments.Molecular Cancer 2007, 6:18 http://www.molecular-cancer.com/content/6/1/18
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for 48 h (Figure 2D). Migration of PC3/OPN cells was sig-
nificantly greater than that of PC3 or PC3/OPN (RGA)
cells; migration rates are in the order of PC3/OPN > PC3
= PC3/OPN (RGA) > PC3/SiRNA. Statistical analysis is
provided as a graph in Figure 2E. These results suggest that
the increase in motility of PC3/OPN cells is due to the
interaction of RGD with the αvβ3 integrin, as PC3/OPN
(RGA) exhibit basal level migration.
Analysis of surface interaction of CD44 with MMP-9
Surface association of CD44 with MMP-9 was shown to
provide a mechanism for tumor invasion in mouse mam-
mary carcinoma and human melanoma cells [19]. Expres-
sion of antisense CD44 and treatment of cells with anti-
CD44 blocked hyaluronic acid (HA)-dependent MMP-2
secretion and, subsequently, invasion of a human lung
carcinoma cell line [27]. Given the above observations,
which implicate CD44 and MMP-9 in tumor invasion, we
sought to determine the surface interaction of these pro-
teins in PC3 cell lines labeled with NHS-Biotin (Figure 3).
In order to further corroborate the interaction of MMP-9
with CD44, PC3/OPN cells were also treated with a block-
ing antibody to CD44 (30 μg/ml; Figure 3, lane 5) prior to
labeling with NHS-Biotin. Lysates were immunoprecipi-
tated with a variant CD44 (vCD44) antibody (lanes 2–5)
or a non-immune serum (NI, lane 6) and subsequently
pulled down with streptavidin agarose. MMP-9 activity
associated with the CD44-immunecomplex was analyzed
by zymogram analysis as described in the Methods sec-
tion. Zymogram analysis of one half of the immunopre-
cipitates is shown in Figure 3A. An increase in CD44-
associated MMP- 9 activity was observed on the surface of
PC3/OPN cells (Panel A, lane 4). Very minimal activity
was observed in PC3 (lane 2) or PC3/OPN (RGA) cells
(lane 3). We observed that pretreatment of PC3/OPN cells
with a neutralizing antibody against CD44 clearly blocked
the OPN-induced activation of MMP-9 (lane 5). PC3 cells
secrete active MMP-9 (Figures 1 and 4) although the inter-
action of both pro- and active MMP-9 was observed on the
cell surface. These results suggest that the surface expres-
sion of CD44 is required for the activation of MMP-9.
Secretion of active MMP-9 by PC3 cells may offer a poten-
tial mechanistic explanation for the processes of ECM deg-
radation and cell migration.
The other half of the immunoprecipitate was blotted with
streptavidin HRP to detect surface levels of CD44 (Figure
3B). In agreement with the data shown in Figure 2, OPN
over expression was associated with an up-regulation of
vCD44 on the cell surface (Figure 3B, lane 1) as compared
with PC3 cells (lane 2). This was not observed in either
PC3/OPN (RGA) (lane 4) cells or in PC3/OPN cells
treated with a blocking antibody to CD44 (lane 5). A sig-
nificant decrease in the surface expression of CD44 was
observed in these cells (lanes 4 and 5). The mechanism by
which anti-CD44 blocks CD44 surface expression is not
well understood. OPN/CD44 interaction was shown to be
required for cell migration and CD44 synthesis [6]. Based
on this observation, we suggest that the failure of interac-
tion of OPN with CD44 by anti-CD44 may reduce CD44
synthesis and surface expression. Changes in the levels of
CD44 expression in PC3/OPN and PC3/OPN (RGA) pro-
vide insights into the role of the αvβ3 receptor in this
process.
Stripping and reprobing of the above blot with an anti-
body to MMP-9 demonstrated the levels of MMP-9 inter-
action with CD44 (Figure 3C). MMP-9 levels
corresponded to the surface expression level of CD44 in
the indicated cell lines (panel C). Immunoprecipitation
with a non-immune serum is shown in lane 3 (B and C).
These observations suggest a biochemical pathway in
which OPN mediated an increase in MMP-9 activity. This
activity may take place via an increase in the surface
expression of MMP-9 docking protein CD44 through
αvβ3-mediated signaling [22,28]. These data demonstrate
a role for CD44 in the surface localization of MMP-9.
The effects of BPs on MMP- 9 activity, migration, and 
proliferation of PC3 cells
Zymogram analysis of conditioned media of PC 3 cell
lines treated with BPs: Giruado et al. have demonstrated
that an amino-bisphosphonate zoledronic acid targets
MMP-9 expressing macrophages and angiogenesis to
impair cervical carcinogenesis [29]. MMP-9 secretion was
dose-dependently down-regulated by clodronate in
human monocyte/macrophages [30]. Bisphosphonate
reduced the activities of MMP-2 and MMP-9 in PC3 cells
[31]. To this end, we investigated whether such inhibitory
effects of MMP-9 activity by bisphosphonates would
block cell migration and proliferation of PC3 cells. First,
conditioned media from the indicated cell lines treated
with or without BPs (50 μM each) such as alendronate
(AL) and pamidronate (PA) for 48 h (Figure 4) were sub-
jected to gelatin zymography. Consistent with the obser-
vation shown by others [31], treatment of the indicated
PC3 cell lines with BPs, resulted in the reduction of MMP-
9 activity in all the cell lines. As shown in Figure 1, MMP-
9 activity was greater in PC3/OPN (Figure 4A, lane 5) than
in PC 3 (lane 2) or PC3/OPN (RGA) cells (lane 8). The
MMP-9 activity observed in alendronate-treated PC3 and
PC3/OPN cells (lanes 3 and 6) is comparable to the activ-
ity observed in untreated PC3/OPN (RGA) (lane 8) or
PC3/SiRNA (Figure 1C, lane 6) cells. It appears that the
reduced cellular level of OPN itself has an inhibitory effect
comparable to that of bisphosphonate. In the immunob-
lotting analysis with an antibody to MMP-9 (Figure 4B),
no significant difference in the secreted level of MMP-9
protein was observed in the indicated PC3 cell lines
treated with (lanes 4–6) or without (lanes 1–3) pamidro-Molecular Cancer 2007, 6:18 http://www.molecular-cancer.com/content/6/1/18
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nate for 48 h. MMP-9 activity but not the secreted level of
MMP-9 is affected by BP treatment or OPN expression.
The MMP-9 activity in the conditioned medium goes
together with the surface expression levels of CD44 (Fig-
ure 2) in different PC3 cells. These data indicate that the
actions of BPs or αvβ3-signaling involve MMP-9 activity
as a principle therapeutic target for the control of cancer
cell progression and metastasis.
Wound closure assay
We next performed wound closure assay in the presence
and absence of BP (Figure 4E and 4F) for 48 h. PC3 and
PC3/OPN cells were used for this assay. To determine the
functional consequences of MMP-9 on cell migration, we
performed this assay in the presence of GM6001, a broad-
spectrum inhibitor of MMPs (GM, Figures 4G and 4H) for
48 h. Untreated PC3 (panel C) and PC3/OPN (panel D)
cells were used as controls. Consistent with the observa-
tion shown in Figure 2, PC3/OPN cells exhibited a signif-
icant increase in migration (Figure 4D). The increase in
migration was not due to proliferation of cells as mitomy-
cin was used to block proliferation. A significant decrease
in the rate of wound closure was observed in PC3 and
PC3/OPN treated with either pamidronate (PA; Figures 4E
and 4F) or GM6001 (GM; Figures 4G and 4H). The num-
bers at the bottom of each panel represent the distance (in
μm) not healed by the migration of cells.
Cell proliferation assay: We then evaluated the anti-prolif-
eration effect of BPs on PC3 cells. Cells were treated with
increasing doses of pamidronate for 48 h. The dotted line
in Figure 4D indicates the initial cell number plated at 0
h. A dose dependent decrease in cell growth was observed
from 10–100 μM pamidronate (Fig.4 4I). Nevertheless,
PA did not induce any apoptosis up to a dose of 100 μM
pamidronate for 48 h. The decrease in cell number sug-
gests the anti-proliferation or anti-cancer effect of BPs.
The effects of BPs on the surface interaction of MMP-9 
and CD44
Rho signaling pathway is a target for BPs. Rho signaling is
essential for CD44 surface expression in osteoclasts [32].
The fact that the expression of Rho GTPase induces clus-
tering of CD44 and MMP-9 in the advancing lamellipodia
of endothelial cells [33] prompted us to determine the
effects BP on the localization of CD44 and MMP-9 in the
indicated PC3 cell lines. The effect of BPs on the surface
interaction of CD44 and MMP-9 was analyzed by immu-
nostaining analysis with respective antibodies in cells that
were neither fixed with paraformaldehyde nor perme-
ablized with Triton X-100 (Figure 5). We found that PC3
cells express MMP-9 (green) throughout the cytoplasm;
however colocalization (yellow) of CD44 (red) and
MMP- 9 (green) was observed as clusters on the surface of
both PC3 (Figure 5A) and PC3/OPN (Figure 5B) cells.
Analysis of surface interaction of CD44 with MMP-9 in differ- ent PC3 cell lines Figure 3
Analysis of surface interaction of CD44 with MMP-9 
in different PC3 cell lines. Equal amount of proteins were 
immunoprecipitated with a vCD44 antibody or a non-
immune serum as indicated in panels A and B. Immune com-
plexes were subsequently pull-down with streptavidin agar-
ose. A. One half of the immunoprecipitates were analyzed 
for MMP-9 activity associated with CD44 by zymogram anal-
ysis as described in the Methods section. Activity of a recom-
binant MMP-9 protein was used as an identification marker 
(lane 1). Arrows indicate pro- and active MMP-9 proteins. B 
and C. The second half of the immunoprecipitate was blotted 
with streptavidin HRP to detect surface levels of CD44 (B) 
and then immunoblotted with anti-MMP-9 (C) after stripping. 
The results represent one of the three separate experiments 
performed.Molecular Cancer 2007, 6:18 http://www.molecular-cancer.com/content/6/1/18
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Bisphosphonate treatment significantly reduces colocali-
zation of CD44 and MMP-9 in PC3 as well as in PC3/OPN
cells (A' and B'). As shown in Figure 2B, PC3/OPN (RGA)
cells had a reduced surface level of CD44 (red). Bisphos-
phonate untreated (C) or treated (C') PC3/OPN (RGA)
cells showed negligible colocalization of CD44 and MMP-
9. The diffused distribution of MMP-9 was observed on
the surface of these cells. The inhibition level of CD44/
MMP-9 interaction in untreated PC3/OPN(RGA) cells (C)
is relatively similar to the level observed in PC3 (A') and
PC3/OPN cells (B') treated with BP. These results suggest
that BP either partially or completely blocks the signaling
The effects of bisphosphonates on MMP-9 activity and migration of different PC3 cells Figure 4
The effects of bisphosphonates on MMP-9 activity and migration of different PC3 cells. A. The effect of BPs, such 
as alendronate (AL, lanes 3, 6, and 9) and pamidronate (PA, lanes 4, 7, and 10) on MMP-9 activity is shown by gelatin zymogra-
phy. MMP-9 activity was determined in the conditioned media of different PC3 cells indicated in the figure. Untreated cells 
were used as controls (lanes 2, 5, and 8). The activity of a recombinant MMP-9 protein was used as an identification control. 
Arrows indicate pro- and active forms of MMP-9. The results represent one of three separate experiments performed. B. The 
effect of BP on the total cellular levels of MMP-9 was determined by immunoblotting with an antibody to MMP-9. No significant 
changes in the total cellular levels of MMP-9 were observed in response to BP treatment. C-H. The effects of pamidronate 
(PA) and GM6001 (GM) on the migration of PC3 cell lines are shown by a wound closure assay. Statistical analysis is provided 
at the bottom of each panel as unhealed wound distance (in μm) at 48 h with (+) and without (-) pamidronate (panels E and F) 
or GM6001 (panels G and H). The data represent the mean ± SEM of triplicate determinations of three different experiments. 
I. The effects of pamidronate on the proliferation of PC3 cells. Dotted line indicates the initial cell number at the time of plating 
(2.5 × 104 cells). PC3 cells were treated with 10–100 μM PA for 48 h. A dose dependent decrease in the proliferation was 
observed in response to PA treatment. Data represent a total of three independent experiments and are expressed as mean ± 
SEM.Molecular Cancer 2007, 6:18 http://www.molecular-cancer.com/content/6/1/18
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pathway mediated by integrin αvβ3. MMP-s are Zn-
dependent endopeptidases. In an attempt to further eluci-
date that the interaction of CD44 and MMP-9 on the cell
surface is specific, we performed immunostaining analysis
with an antibody to human Zip-1 (hZip-1). Human Zip-1
is a cell surface zinc transporter protein that was shown to
be expressed ubiquitously on the surface of prostate can-
cer cells [34]. Immunostaining analysis revealed that the
interaction of hZip-1 with either CD44 or MMP-9 was
negligible or not at all observed (data not shown). A sig-
nificant increase in the coclustering of CD44 and MMP-9
on the cell surface of PC3/OPN cells as compared with
PC3 cells (Figure 5A and 5B) suggest a plausible mecha-
nism of activation of MMP-9 by CD44.
Analysis of the effects of osteopontin over-expression on 
cell morphology and RANKL expression in PC3 cell lines
Analysis of morphology of live PC3 cells by phase contrast
microscopy: Over-expression of OPN has been shown to
augment the occurrence of multinucleated giant cells in
pancreatic adenocarcinoma [35] and macrophages of rat
glomerulonephritis [36]. These observations prompted
investigation on cell morphology in PC3 cell lines that
have been used for the above-mentioned studies (Figure
6A). We demonstrated here that the number of multinu-
cleated giant cells was increased in PC3/OPN cells. PC3/
RGA cells have multinucleated giant cells at a level com-
parable to that of PC3 cells. PC3/SiRNA cells failed to dis-
play multinucleated giant cells (Figure 6A). In our
observations, repeated passaging of PC3/OPN has no
effect on the survival of multinucleated giant cells, indi-
cating the genomic stability of this cell line.
Analysis of expression of RANKL by immunoblotting analysis
The addition of OPN increased the expression of RANKL
and augmented the differentiation of osteoclasts from
OPN deficient mice [37]. Since PC3/OPN cells displayed
multinucleated giant cells, we presumed that an increased
expression of RANKL may be the causative factor for this
phenotype (Figure 6B). Immunoblotting analysis with an
antibody to RANKL indeed revealed an increased expres-
sion of RANKL in PC3/OPN cells (lane 2) as compared
with the other PC3 cell lines (lanes 1, 3 and 4). Stripping
and reprobing of the same blot with an antibody to
GAPDH was used as an internal control for normaliza-
tion. These observations are in keeping with the observa-
tion of Ishi et al., that OPN increased the expression of
RANKL [37].
Discussion
Osteopontin expression has been related to the metastasis
of tumor cells [38,39]. OPN functions as a paracrine and
autocrine mediator of prostate cancer growth and progres-
sion [25]. The biological events that mediate the progres-
sion of prostate cancer are not well defined. It was
suggested that signaling mediated by integrin αvβ3 facili-
tated prostate cancer cell progression into bone through
their adhesion to and migration on OPN and VN. These
are common RGD containing ECM proteins in the bone
microenvironment [40]. Our aim was to elucidate the
possible role of OPN and its receptor(s)-mediated down-
stream signals in the progression of prostate cancer cells.
The data presented here demonstrates the following: a)
OPN over expression increases the interaction of CD44
and MMP-9 on the cell surface; b) integrin and CD44 sig-
naling act as key regulators of MMP- 9 activation; c) the
regulation of MMP- 9 occurs through the activation of
latent proenzyme (pro MMP-9) on the cell surface; d)
OPN/αvβ3-mediated signaling and CD44 expression on
the cell surface delineate a likely mechanism in MMP-9
activation and prostate cancer cell migration; e) an
increased expression of RANKL in prostate cancer cells
provides a plausible additional mechanism in the signal-
ing pathway that leads to CD44 surface expression and
MMP-9 activation.
De novo expression of CD44 and its variant isoforms has
been associated with the aggressive behavior of various
tumors [41,42]. Most widely studied CD44 in clinical can-
cers are probably CD44s, CD44v6, and CD44v3 [43].
CD44v6 and v9 were shown to frequently express in pros-
tate cancer. Our results showed that PC3 cells express mul-
tiple high molecular weight isoforms (CD44v) and
CD44s core molecule on the cell surface in an OPN/αvβ3
-dependent manner (Figures 2 and 3). Expression of these
proteins is increased in PC3/OPN cells. Although, OPN
has been shown to be an important ligand for CD44, our
data suggests that OPN up-regulated cell invasiveness in
an RGD and integrin-dependent manner of CD44 activa-
tion rather than having a direct effect on vCD44 in PC3
cells. The vCD44 isoform(s) that has prognostic signifi-
cance in the metastasis of prostate cancer cells remains to
be explored. We suggest that the characterization of
vCD44 isoforms necessitates additional studies to unravel
its role in cell migration.
We have shown an interaction of MMP-9 with cell surface
receptor CD44. Although MMPs interaction with cell
adhesion receptors has been observed in different cell sys-
tems [19,44-48], the actual mechanism by which they are
processed and activated on the cell surface and secreted as
an active form is not yet known. OPN expression and
MMP-9 activity are linked to prostate cancer cell progres-
sion and metastasis [3,39,40]. Active MMP-9 has been
found in association with the vCD44 isoform on the inva-
dopodia of breast cancer cells [33,46,49]. We have previ-
ously shown the interaction of MMP-2 with cell surface
CD44 in human melanoma cells over expressing OPN
[10]. In the present study, we show that the surface expres-
sion of CD44 and the interaction of CD44 with MMP-9Molecular Cancer 2007, 6:18 http://www.molecular-cancer.com/content/6/1/18
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was reduced in PC3/OPN (RGA) cells as compared with
PC3 and PC3/OPN cells (Figures 2, 3, and 5). However,
no changes were observed on the surface levels of MMP-9
(Figures 2 and 5). A decrease in MMP-9 interaction with
CD44 on the cell surface and secretion of MMP- 9 suggests
a role for integrin αvβ3 signaling in the surface expression
of CD44.
Cell surface receptors have been shown to provide a dock-
ing mechanism for MMPs [10,19,50]. CD44 associates
with MMP- 9 on the cell surface of mammary carcinoma
and melanoma cells. The inhibition of surface interaction
of these proteins by over expression of soluble or trun-
cated CD44 blocked migration and tumor invasion. These
observations suggest that CD44/MMP-9 interaction on
the cell surface has a role in tumor progression [19]. We
show here coclustering of CD44/MMP-9 on the surface is
dependent on the expression levels of OPN and CD44 as
well as integrin αvβ3 signaling. Pretreatment of PC3/OPN
cells with a neutralizing antibody to CD44 competitively
blocked the activity of CD44-associated MMP-9 on the
surface (Fig. 3). As shown by others [19] and in the
present study, CD44 expression on the cell surface may
define a mechanism for MMP-9 activation and cancer cell
migration.
We have shown secretion of active MMP-9 as well as pro-
and active MMP-2 by all the PC3 cells. Integrin αvβ3/
CD44 signaling mechanism regulates the secretion of
MMP-9 and not MMP-2. It is possible that MMP-2 can be
activated by different signaling pathway in prostate cancer
cells. Similar to the observation shown here, secretion of
an active form of MMP-9 was shown in metastatic breast
cancer cells [48]. Secretion of an active form of MMP-9 is
more in PC3/OPN cells than PC3/OPN (RGA) or PC3/
SiRNA cells (Figures 1 and 4A). However, immunoblot-
ting analysis exhibited equal levels of MMP- 9 protein in
the conditioned medium (Figure 4B). Although, a large
excess of MMP-9 protein is secreted by all these cell lines,
the levels of MMP-9 activity in the conditioned medium
mirror the pattern of CD44 surface expression. This indi-
cates that portion of this protein can be secreted as or
Immunostaining analysis of the effect of BP on the surface interaction of CD44 and MMP-9 in PC3 cell lines Figure 5
Immunostaining analysis of the effect of BP on the surface interaction of CD44 and MMP-9 in PC3 cell lines. 
Confocal microscopy analysis of distribution of CD44 (red) and MMP-9 (green) in PC3 cell lines treated with (+, A' to C') or 
without (-, A-C) pamidronate is shown. Yellow color indicates colocalization of proteins on the cell surface. The results repre-
sent one of three experiments performed. Scale Bar-50 μm.Molecular Cancer 2007, 6:18 http://www.molecular-cancer.com/content/6/1/18
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turned into an inactive form. Lack of pro or intermittent
form of MMP-9 in the gelatin zymography supports this
conclusion (Figures 1 and 4). The mechanism by which
the inactive MMP-9 is secreted needs to be investigated.
Secretion of active MMP-9 seems to be dependent on the
cooperative interaction between the two cell surface recep-
tors, integrin αvβ3 and CD44.
We show here the inhibitory effect of bisphosphonates
(e.g. alendronate and pamidronate) on MMP-9 activity,
CD44 surface expression, cell surface CD44/MMP-9 inter-
action, and migration (Figs. 4 and 5); without increasing
apoptosis of cells. The data are consistent with the obser-
vations by Bossier et al that BP blocks tumor cell invasion
by the inhibition of proteolytic activity of MMPs but not
by inducing apoptosis [20]. Alendronate blocked MMPs
secretion and bone collagen release by PC3 cells in SCID
mice [51]. Recent findings have shown that alendronate
and other BPs block the mevalonate pathway, thereby pre-
venting prenylation of small GTPase signaling proteins
that are required for both osteoclast function [52,53] and
human ovarian cancer cell migration [54]. It has been sug-
gested that Rho A triggers signaling pathways that upregu-
lated the expression of MMP-9 at specific membrane
localizations. These localizations may confer a highly
invasive phenotype to endothelial cells [33]. We have pre-
viously shown that OPN/αvβ3-mediated Rho signaling is
required for CD44 surface expression [22]. Based on these
findings, we postulate the notion that decreased Rho sig-
naling by BPs could be responsible for the reduced surface
expression of CD44, surface interaction of CD44/MMP-9,
and cell migration (Figures 4 and 5) in PC3 and PC3/OPN
cells.
Bone metastases are a common occurrence in a number of
cancers including lung, breast, and prostate. Bone resorp-
tion markers were found to be elevated in patients with
prostate cancer and bone metastasis [55]. Bisphospho-
nates are inhibitors of bone resorption mediated by oste-
oclasts and were shown to reduce bone pain from
metastatic prostate cancer [56]. Prostate cancer cells in
bone have been shown to secrete factors such as, PTHrP
and RANKL [57-59]. It was shown recently that tumor
metastatic activities is mediated by OPG/RANK/RANKL/
MMP-9 signaling in PC3 cells and is inhibited by genistein
[58]. Expression of OPG/RANK/RANKL in cancer cells has
been suggested to have a role in the expression and activ-
ity of MMP-9 as well as cancer metastasis [60,61].
As OPN expression has been shown to increase RANKL
expression [37], we analyzed the levels of RANKL in PC3
cell lines. A decrease in the level of RANKL in PC3/OPN
(RGA) as compared with PC3/OPN cells suggests that
αvβ3 signaling may have a role in the expression of
RANKL. Similar to OPN/αvβ3 in the regulation of Rho
signaling pathway [22], RANKL also induces Rho signal-
ing pathways in osteoclasts [62]. It is possible that a
cumulative increase in Rho activation through αvβ3- and
RANKL-mediated down stream signaling pathway may
have a direct effect on the surface expression of CD44 in
PC3/OPN cells (Figure 7-Scheme). Bisphosphonate was
shown to block the mevalonate pathway that inhibits
small Rho GTPases [52], which was shown to be crucial
for CD44 surface expression [22]. Bisphosphonates also
down regulate the expression levels of RANKL in osteosa-
rcoma cells [63]. Finally, one must consider the possibility
that the increase in CD44 surface expression, MMP-9 acti-
vation, and the migration of prostate cancer cells may
occur through multiple down stream signaling pathways
that are instigated by αvβ3 receptor.
Conclusion
Observation in different PC3 cell lines indicate an under-
lying correlation between the surface levels of CD44 and
secretion of active form of MMP- 9 in prostate cancer cells.
These results, taken together, suggest some prognostic
importance of OPN protein and integrin αvβ3 signaling
pathway in the possible vicious action of tumor cells and
underlying pathology. The coordinated regulation of pro-
teins such as OPN, αvβ3, RANKL, CD44, and MMP-9 may
provide a physiological mechanism for prostate cancer
cells to promote migration during metastasis.
Analysis of the effects of OPN over expression on cell mor- phology and RANKL expression in PC3 cell lines Figure 6
Analysis of the effects of OPN over expression on cell 
morphology and RANKL expression in PC3 cell lines. 
A. Indicated PC3 cell lines were photographed using a phase 
contrast microscope. An increase in multinucleated giant 
cells was observed in PC3/OPN cells (magnification × 200). 
B. Immunoblotting analysis of RANKL expression in PC3 cell 
lines Immunoblotting analysis in protein lysates made from 
the indicated cell lines was performed with an antibody to 
RANKL. PC3/OPN cells express greater level of RANKL 
that PC3 cells. Results shown are a representation of three 
independent experiments. Bottom panel shows normaliza-
tion with GAPDH.Molecular Cancer 2007, 6:18 http://www.molecular-cancer.com/content/6/1/18
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Methods
Reagents
Antibodies to the standard and variant (V3–V10) CD44
were purchased from Biosource International, Inc.
(Camarillo, CA). Antibodies to MMP-2 and MMP-9 were
purchased from Chemicon International, Inc. (Temecula,
CA). Cy2- and Cy3-conjugated secondary antibodies were
purchased from Jackson Immunoresearch Laboratories,
Inc. (West Grove, PA). GAPDH antibody was purchased
from Abcam, Inc. (Cambridge, MA). Biotin (EZ-link
Sulfo-NHS-LC Biotin), streptavidin-HRP, and ECL- rea-
gent were bought from Pierce (Rockford, IL).
cDNA constructs, cell lines and culture
Mutation in the integrin-binding motif (Arg-Gly-Asp
[RGD] Δ Arg-Gly-Ala [RGA]) of human OPN [21] was
A schematic representation of osteopontin/αvβ3 signaling in the regulation of prostate cancer cell migration Figure 7
A schematic representation of osteopontin/αvβ3 signaling in the regulation of prostate cancer cell migration. 
PC3 cells bind osteopontin through integrin αvβ3 in an RGD-dependent manner. Integrin αvβ3 increases Rho GTPase activity 
through down stream signaling pathway that involves RANKL [62] or tyrosine phosphorylation of several signaling molecules 
such as Src, PYK2, FAK, and p130Cas associated with integrin [10,64]. Rho activation increases CD44 surface expression 
[10,32] that resulted in the activation of MMP-9. The interaction of CD44 with MMP-9 on the cell surface may have a role in 
the degradation of ECM to facilitate cell migration. Bisphosphonates (BPs) inhibit CD44 surface interaction with MMP-9 either 
partially or completely. The signaling pathway and the target molecules that exhibit the inhibitory effects of BP treatment are 
indicated by dotted arrows and 'X'. A decrease (indicated by inverted red arrow) in CD44 surface expression, MMP-9 interac-
tion with CD44 on the cell surface, MMP-9 secretion, and cell migration was observed in cells treated with BP. PC3/OPN cells 
treated with BPs reproduce the changes observed in PC3/SiRNA and PC3/OPN (RGA) The possible reason for these effects 
may be due to reduced αvβ3 -signaling in PC3/OPN (RGA) and PC3/SiRNA cells or targeting of αvβ3-signaling pathway by BPs.Molecular Cancer 2007, 6:18 http://www.molecular-cancer.com/content/6/1/18
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generated using altered sites II in vitro mutagenesis system
(Promega, Madison WI). Prostate cancer epithelial cells
(PC3, CRL-1435; ATCC; Manassas, VA) were transfected
with full-length (PC3/OPN), mutant OPN (PC3/OPN
[RGA]) in pCEP4 vector, and vector without insert
(pCEP4) with use of Lipofectamine 2000 (Invitrogen,
USA) following the manufacturer's instructions.
The OPN SiRNA expression vector was generated using
Seqwright DNA Technology Services (Houston, TX). A
minimum of four SiRNA constructs for the OPN gene
were generated to allow selection of one that expresses an
optimal silencing effect. Scrambled RNA construct was
used as a control for SiRNA constructs. For each construct,
two oligonucleotides that encode sense and antisense
sequences separated by a short spacer region (approxi-
mately 5–7 bp, forming the loop structure) were designed
and synthesized. Location of the target sequence for the
constructs are 126–146, 383–403, 649–669, 869–889 in
OPN cDNA. PC3 cells were transfected with the SiRNA
constructs and pSilencer 4.1-CMV neo vector (as vector
control) using a silencer SiRNA transfection kit (Ambion,
Austin, TX).
Individual clones (about 15–20) were isolated following
transfection of PC3 cells with the above-mentioned OPN
constructs. PC3 cells were transfected with use of Lipo-
fectamine 2000 (Invitrogen, USA) following the manufac-
turer's instructions. After 48 h transfection, cells were
maintained in medium that contained different concen-
trations of G418 sulfate, for selection. Cells were kept in
400 μg/ml G418 for 3 d followed by 200 μg/ml G418 sul-
fate for 7–10 days and continued in 100 μg/ml G418 for
20 days. After selection, G418-resistant clones were
observed as cell clusters. Individual clones were isolated
for each construct in 24-well tissue culture plates using
cloning filters (Sigma). Once the small cultures grew to
near confluency, they were transferred to 60 mm tissue
culture dishes with RPMI medium containing 10% FBS.
Clones were maintained individually for each construct.
OPN expression levels were determined by immunoblot-
ting analysis with a polyclonal antibody to OPN (gener-
ated in Sigma-GenoSys). Four clones (C1–C4) that
express elevated levels of full-length and mutated OPN
(RGDΔRGA) were selected. To reduce the endogenous lev-
els of OPN, four different SiRNA constructs were trans-
fected into PC3 cells. PC3 cells transfected with respective
vectors and untransfected PC3 cells were used as controls.
Maximum decrease was observed with a SiRNA construct
targeted to sequence 383–403 in human OPN cDNA.
Individual clones (C1–C5) that exhibited maximum
reduction in endogenous OPN levels were generated from
this cell line. PC3 clones that express the highest levels of
OPN (full length and mutant) and a maximum reduction
in the endogenous levels of OPN were used for all the
experiments described here. These clones were designated
as PC3/OPN, PC3/OPN (RGA) and PC3/SiRNA.
Cell culture and Treatments
PC3 cell lines were cultured in Roswell Park Memorial
Institute-1640 (RPMI-1640) media containing 10% FBS
at 37°C (Gibco-BRL, Bethesda, MA). Bisphosphonates
(BPs), such as alendronate and pamidronate were used for
experiments. Stocks (1 mM) were made in PBS or sterile
H2O. Prostate cancer cells were treated with BPs to a final
concentration of 50 μM for 48 h at 37°C. Some cultures
were treated either with the blocking antibody to CD44
(30–50 μg/ml; BioSource AHS 4418) or GM6001 (15 μM
at 37°C) for 48 h. Following various treatments, cells were
washed three times with cold PBS and lysed with RIPA
lysis buffer as described previously [22]. Some cultures
were used for immunostaining analysis as described
below. For zymogram analysis, cells were kept in serum-
free RPMI medium for 24–48 h in the presence and
absence of various treatments. Conditioned media col-
lected from various PC3 cell lines were subjected to gela-
tin zymography as described below and previously [10].
Immunostaining
Surface localization of CD44 and MMP-9 was determined
in cells that were not permeablized with paraformalde-
hyde or fixed with Triton X-100 by immunostaining with
antibodies to variant CD44 (V3–V10) and MMP-9 as
described previously [22].
Cell surface labeling by biotinylation and Immunoblotting 
analysis
After various treatments, cells were labeled with NHS-
biotin according to the manufacturer's guidelines (Pierce,
Rockford, IL). Briefly, cells were incubated with 0.5 mg/
ml biotin for 30–40 min. at 4°C and washed three times
with cold PBS. Cells were lysed with RIPA lysis buffer as
described previously [22]. Equal amounts of protein
lysates were used for immunoprecipitation with an anti-
body to CD44 or MMP-9. Immunopecipitation of two
proteins at the same time with two different antibodies
(e.g. CD44 and actin as shown in Figure 2) was also per-
formed. The immune complexes were adsorbed onto Pro-
tein-A sepharose beads or streptavidin agarose.
Streptavidin agarose precipitates the biotinylated CD44
protein from the cell surface. The immune complexes
adsorbed onto streptavidin agarose were washed three
times with cold PBS and incubated with sample buffer
with no reducing agent (β ME or DTT) for 10–15 min. at
room temperature (RT). Zymogram analysis was per-
formed as described below. MMP-9 activity associated
with cell surface CD44 was analyzed by gelatin zymogra-
phy as described below. The immune complexes adsorbed
onto streptavidin agarose were also used for immunoblot-
ting analysis with streptavidin-HRP to detect the cell sur-Molecular Cancer 2007, 6:18 http://www.molecular-cancer.com/content/6/1/18
Page 14 of 16
(page number not for citation purposes)
face levels of CD44. The immune complexes adsorbed to
Protein-A sepharose beads were immunoblotted with
streptavidin HRP to detect the surface level of CD44 or
with a primary antibody of interest (e.g. actin). Immuno-
blotting with an actin antibody was used as a loading con-
trol. Prior to loading on SDS-PAGE, these samples were
boiled with loading buffer containing βME. SDS-PAGE
analysis and immunoblotting was performed as described
previously [22,23]. Protein bands were visualized by
chemiluminescence using the ECL-kit (Pierce, Rockford,
IL).
Gelatin zymography
Conditioned media collected from various PC3 cell lines
were concentrated approximately 10-fold) with a centri-
con concentrator (Amicon, Beverly, MA). Ten micrograms
of concentrated media protein was diluted to 20 μl in cold
PBS. Immune complex made with CD44 (V3–V10) anti-
body, as described above, was also used for this analysis.
Samples were mixed with SDS gel loading buffer with no
reducing agent (βME or DTT) and incubated at RT for 10–
15 min to dissociate immune complexes. SDS-PAGE con-
taining 0.1% gelatin was used for electrophoresis. Sam-
ples were loaded without heating with sample buffer.
After electrophoresis, gels were incubated overnight in a
buffer containing 50 mM Tris-HCl, pH 7.6, 5 mM CaCl2,
1 μM ZnCl2, and 1% Triton X-100. Triton was used to
remove SDS from the gel. Gels were then stained with
coomassie brilliant blue for 2–3 h and destained with 7%
acetic acid or water. Gelatinolytic activity was detected as
clear bands in the background of blue staining [24].
Analysis of cell migration by wound closure assay
Wound closure assay was performed as described previ-
ously [10]. Cells were grown in 35 mm culture plates (Fal-
con) to near-confluent level in RPMI medium containing
10% fetal bovine serum (FBS; Cellgro). Multiple uniform
streaks (~50 μm in width) were made on the monolayer
culture with 10 μl pipette tips. The cells were immediately
washed with RPMI-medium with 10% FBS to remove
detached cells. Mitomycin (5 μg/ml; Sigma) was used in
the medium to inhibit proliferation of cancer cells. Hence,
the observed increase in PC3 cells is not due to increase in
proliferation of cells. The experiment was performed with
GM6001 (15 μM) and bisphosphonates (50 μM). The cell
migration was monitored for 48 h, and pictures were
taken at 0 h and 48 h time points with a digital SPOT cam-
era attached to an inverted Nikon phase contrast micro-
scope. Six to eight fields were analyzed, and the mean
percentage of wound area covered by cells was calculated.
The amount of wound closure remaining between the
original wound widths was traced with SPOT Advanced
3.0.4 image software (Diagnostic Instruments, Inc.). The
distance between the migratory cells in the wound area at
a 90° angle to the wound margin generated at 0 h was
measured using the same program. The distance of wound
width was expressed in microns before and after migra-
tion. Following each experiment, cell viability was con-
firmed by trypan blue dye exclusion assay. Floating cells
were marked with black arrows (Figures 2 and 4). Statisti-
cal analysis was performed as described below.
Cell proliferation assay
PC3 cells were plated in 6-well chambers at a confluence
of 2.5 × 104 cells per well in RPMI-1640 medium contain-
ing 10% FBS at 37°C for 18 hours. Cells were then treated
with increasing doses of pamidronate as indicated. Cells
treated with PBS were used as controls. Incubation was
continued for 48 h. Cells were counted using a Neubauer's
chamber at the end of 48 hours.
Statistical analysis
All values presented as mean ± SEM. A value of p < 0.05
was considered significant. Statistical significance was
determined by analysis of variance (ANOVA) with the
Bonferonni corrections (Instat for IBM; Graphpad soft-
ware).
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